Episode
E135: IL17 and a GLP1?
- Published
- Apr 30, 2026
- Duration seconds
- 663
- Processing state
not_requested- Canonical source
- https://msputman.podbean.com/e/e135-il17-and-a-glp1/
Actions
POST https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e135-il17-and-a-glp1/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e135-il17-and-a-glp1.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Really interesting study this week comparing the IL17 inhibitor ixekizumab WITH the GLP1 inhibitor tirzepatide to ixekizumab alone. Raises some interesting questions about what worked here and whether or not it matters how it worked. Paper: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.70134 Newsletter: http://autoimmunedevreport.com/